From their founding, Historically Black Colleges and Universities (HBCUs) educated as many as 90 percent of Black college students in the United States. Although many are aware of the significance of HBCUs for expanding Black Americans’ educational opportunities, much less attention has been paid to the vital role that they have played in enhancing American democracy. Drawing on six years of mixed-method research that informs The Power of Black Excellence: HBCUs and the Fight for American Democracy, this book talk considers the history of HBCUs and the unique role they have played in shaping American political development since 1837. Moreover, it considers the lessons that HBCUs offer the broader higher educational landscape as we consider the essential role that colleges and universities can play in helping to promote democracy.Deondra Rose is the Kevin D. Gorter Associate Professor at the Sanford School of Public Policy at Duke University, with secondary appointments in the Department of Political Science and the Department of History. Her research focuses on U.S. higher education policy, political behavior, American political development, and the politics of inequality, particularly in relation to gender, race, and socioeconomic status. In addition to her newest book, The Power of Black Excellence: HBCUs and the Fight for American Democracy, Rose is also the author of Citizens by Degree: Higher Education Policy and the Changing Gender Dynamics of American Citizenship, which examines the development of landmark U.S. higher education policies and their impact on the progress that women have made since the mid-twentieth century. A summa cum laude, Phi Beta Kappa graduate of the University of Georgia, Rose received her M.A. and Ph.D. in Government from Cornell University, with a specialization in American politics and public policy.

KRICT sets a new world record for large-area perovskite solar module efficiency and accelerates commercialization

Source: Dr. Douglas Loe 11/12/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) should benefit from Sana Biotechnology's recent prioritization of its diabetes-targeted cell therapy programs, reported Leede Financial Inc. analyst Dr. Douglas Loe in a Nov. 6 research note. Now Sana's clinical programs in oncology and Huntington's disease are a secondary focus.

"Our model assumes that Sernova's cell reservoir device Cell Pouch will itself remain focused on Type 1 diabetes, and we are thus encouraged to see a U.S. peer prioritize its pipeline in ways that are consistent with our own views on how priorities in regenerative medicine will evolve in coming years," Loe wrote.

500% Potential Return

Leede has a CA$1.50 per share target price on Sernova, trading at the time of the report at about CA$0.25 per share, noted Loe.

"At current price levels, our price target corresponds to a one-year return of 500%, a return that we believe is imminently achievable by 2025E but likely with a milestone-driven, and not a linear, trajectory," the analyst wrote.

The company is a Speculative Buy.

Synergistic Potential Exists

Loe highlighted that Sernova and Sana could benefit from aligning their programs, on a timeline providing synergies to both.

"We are encouraged to see a leading regenerative firm choose to expedite its diabetes cell therapy program in preference to other initiatives that it could fund if it chose to," Loe wrote. "This is consistent with our own view that the most attractive medical market for regenerative firms, and for Sernova, to target is the large and growing diabetes market both for economic and technical reasons."

Sana's Diabetes Programs

Sana's primary focus is its program to treat Type 1 diabetes with its Phase 1-stage, hypo-immune platform (HIP)-modified primary pancreatic islet cell therapy UP421 and its preclinical HIP-modified, stem cell-derived pancreatic islet platform SC451.

Through this platform, regenerative cell therapies can be modified genetically to evade immune detection post implantation. This is achieved by reducing expression of major histocompatibility-complex, classes one and two human leukocyte antigens while increasing expression of CD24. This is a surface protein found on stem cells in the pancreas.

Sernova's Cell Reservoir Platform

As for Sernova, it has a well-vascularized, sustainably functioning cell reservoir platform, Cell Pouch, proven for some time. Development of regenerative islet platform technology is now catching up. Sernova has a clinical trial underway that combines the two technologies. This Phase 1 trial in diabetes, in partnership with the University of Chicago, already has shown "impressive long-term insulin independence data" up to five years in some study participants.

This is "well beyond what we believe is a reasonable threshold for the U.S. Food and Drug Administration to require for future Cell Pouch approval, at least for Type 1 diabetes," Loe wrote.

Currently, with regard to this program, Sernova optimizing background immunosuppression in Cell Pouch patients. Details of its new immunosuppressive regimen are expected in the biotech's next Phase 1 study update, likely in early H1/25.

"Future enrollees could be subjected to novel immunosuppressive therapies that conceivably could extend islet survival and perhaps even reduce the immunosuppressive burden that transplant patients must endure at present," Loe commented.

Further, Sernova is considering conducting a Phase 1 study using its Cell Pouch and Evotec AG's stem-cell-derived iBeta platform to treat diabetes. Before this can happen, though, Evotec needs to be able to produce iBeta at a clinical scale, which Loe expects can happen by H2/25.

"We see no reason why Sana and its UP421/SC451 modified islet platforms could not be incorporated into a Cell Pouch environment as a way to sustain their therapeutic half-life in the body post-implantation," wrote Loe.

Possible Stock Price Movers

Loe provided a handful of potential catalysts for Sernova's share price. They are:

1) Sernova's conclusion of its ongoing Phase 1 study in Type 1 diabetes with the University of Chicago, which Loe asserted should happen a quickly as possible given available capital. Also, the biotech should incorporate into this trial or a separate one to commence soon after, regeneratively produced pancreatic islets.

2) Sernova, in partnership with Sana, launching a Phase 1 iBeta/Cell Pouch trial late next year, which could boost Sernova's share price.

3) Sernova identifying additional developers of regenerative cell therapies with which it could combine Cell Pouch in mutually beneficial ways.

4) Sernova starting clinical programs in hemophilia A and in thyroid disease, expected to happen in the coming quarters.

5) Sernova incorporating its confocal cell coating technology into one or more future protocols for stem cell-derived pancreatic islet production, even its current Phase 1 diabetes trial with the University of Chicago. Before this can happen, however, coating polymer composition and manufacturing methodologies must be honed to meet good manufacturing practices specifications.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., Sernova Corp., November 6, 2024

Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives.

Leede provided investment banking services for the company during the 12 months preceding the publication of the research report.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

The American Industrial Hygiene Association® (AIHA) yesterday announced the recipients of the 2015 AIHA awards, which honor individuals who provide significant contributions to the industrial hygiene and occupational and environmental health and safety profession.

The National Highway Traffic Safety Administration (NHTSA) includes cell phone usage on its list of common driver distractions.

Ronald A. Schneider lends years of expertise to his work with V2X

Michael D. McCann, MD, MBA, is an Assistant Professor of Clinical Medicine at Vanderbilt University Medical Center

Global food company, the Kerry Group, has announced that it will establish its new centre for excellence for bakery products in Melbourne, creating 118 new jobs. The A$13.7 million investment by the company in the Western Melbourne suburb of Altona (18 km from the Melbourne city centre) will be used to purchase state-of-the-art manufacturing equipment, and increase their research and development capacity.

Clinical functional proteomics of intercellular signalling in pancreatic cancer  Nature.com

Ha muerto la dama de las letras: Carmen Balcells. Sin esta gran mujer no hubiese sido posible reunir, en un mismo libro de oro, los nombres más fecundos de la literatura iberoamericana.

All the colors of jazz!

[Written by Stephen Wright] Pollution in the River Seine forced the cancellation of the second and final swimming practice session today [July 29]. Bermuda’s Tyler Smith is scheduled to compete in the men’s race tomorrow, while Dame Flora Duffy and Erica Hawley are due to take to the river for the start of the women’s […]

All of the remaining run of The Pirates of Penzance have been cancelled due to the pending arrival of Hurricane Gonzalo. A statement from the Gilbert & Sullivan Society said, “Dear Gilbert & Sullivan Society of Bermuda patrons, members, cast, crew and audiences,It is with a very heavy heart that we must announce the cancellation […]

The 7th Annual Bermuda Shakespeare Schools Festival, scheduled to be held at the Earl Cameron Theatre this week is cancelled, as the students had missed too many practice times due to both Tropical Storm Fay and Hurricane Gonzalo. A spokesperson said, “We sincerely apologize for any inconvenience this will cause. “We spoke with the teachers at […]

Removed From Troubles (Open for application): Menhera (People)

Here is the audio, video, and transcript. Here is part of the episode summary: In Neal’s second appearance, Tyler asks him why he sometimes shifts from envisioning the future to illustrating the past, the rise of history autodidacts, the implications of leaked secrets from the atomic age to…

A simple biomaterial-based strategy that can influence the behavior of cells could pave the way for more effective medical treatments such as wound healing, cancer therapy and even organ regeneration, according to a research team at Penn State.

Dusit International, one of Thailand’s leading hotel and property development companies, has signed a Memorandum of Understanding (MoU) with Tourism Development Fund (TDF), the national enabler of the tourism sector in Saudi Arabia, to establish a preliminary framework for developing hospitality projects that will enhance the country’s tourism infrastructure.

The Delhi High Court has ordered the Bureau of Immigration to cancel a Look Out Circular (LOC) issued against BharatPe's former Managing Director Ashneer Grover and his wife Madhuri Jain Grover.

The award was presented at the 27th Energy Technology Meet in Bengaluru.

Three railway lines were affected in the derailment. Some trains skipped stoppages.

On the govt.’s allegation of his being involved in “anti-India activities”, the court says the notice lacks specific details or evidence supporting these claims

The cancellation is owing to traffic blocks in the Naupada-Gunupur section of Waltair Division

parcelLab, a global provider of post-purchase experience software, has announced the launch of "Trending Late AI," a new feature powered by artificial intelligence (AI)

Few questions have captivated humankind more than the origin of life on Earth. How did the first living cells come to exist? How did these early protocells develop the structural membranes necessary for cells to thrive and assemble into complex organisms? New research from UC San Diego has uncovered a plausible explanation involving the reaction between two simple molecules.

A chatter emerged that South Africa could be a viable alternative to organise next year's Champions Trophy but no such discussion happened in the International Cricket Council on Tuesday

Extracellular vesicles (EVs) released by various cells play crucial roles in intercellular communication within the respiratory system. This review explores the historical context and significance of research into extracellular vesicles. Categorised into exosomes (sized 30–150 nm), microvesicles (sized 50–1000 nm) and apoptotic bodies (sized 500–2000nm), based on their generation mechanisms, extracellular vesicles carry diverse cargoes of biomolecules, including proteins, lipids and nucleic acids. Respiratory ailments are the primary contributors to both mortality and morbidity across various populations globally, significantly impacting public health. Recent studies have underscored the pivotal role of extracellular vesicles, particularly their cargo content, in mediating intercellular communication between lung cells in respiratory diseases. This comprehensive review provides insights into extracellular vesicle mechanisms and emphasises their significance in major respiratory conditions, including acute lung injury, COPD, pulmonary hypertension, pulmonary fibrosis, asthma and lung cancer.

The upcoming season, created by Sam Levinson, will consist of eight episodes and is expected to include a time jump that catches up with the characters in new stages of their turbulent lives